Research on ipamorelin further supports its anabolic potential, showing an increase in bone mineral content and muscle retention in animal models subjected to catabolic stress
Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough
Results vary for each person based on many factors
So: tirzepatide (marketed), retatrutide (late Phase 3, highest potency), orforglipron (regulatory review, oral convenience), eloralintide (Phase 3 starting, amylin mechanism)
The mechanisms of GLP-1 RAs action in retinopathy and NAION remain incompletely understood, highlighting the need for large trials with baseline retinal grading and extended follow-up